179003-10-2

Usage

Uses

Used in Pharmaceutical Industry:
4-[3-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER is used as a research compound for the development of new therapeutic agents, particularly for central nervous system disorders. Its potential as a CNS depressant and a treatment for anxiety and depression makes it a promising candidate for further investigation and development.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-[3-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER is utilized for studying the structure-activity relationships of piperazinecarboxylic acid derivatives. Understanding how modifications to the molecule affect its pharmacological properties can guide the design of more effective drugs.
Used as a Prodrug:
The 1,1-dimethylethyl ester group in the compound indicates its potential use as a prodrug. It may be metabolized in the body to release the active form of the drug, which could enhance the bioavailability and therapeutic efficacy of the treatment.

InChI:InChI=1/C17H24N2O4/c1-17(2,3)23-16(21)19-10-8-18(9-11-19)14-7-5-6-13(12-14)15(20)22-4/h5-7,12H,8-11H2,1-4H3

Upstream product

• 618-89-3 methyl 3-bromobenzoate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 179003-08-8 3-piperazine-4-yl-benzoic acid methyl ester 
• 618-91-7 methyl 3-iodo-benzoate 
• 446831-28-3 3-(piperazin-1-yl)benzoic acid 
• 4518-10-9 Methyl 3-aminobenzoate 

Downstream Products

• 193818-13-2 4-(3-carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1447332-02-6 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid 
• 1447332-14-0 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid 
• 1447330-37-1 3-[1-oxo-6-(3-piperazinium-1-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]propionic acid trifluoroacetate 
• 1447330-50-8 3-[1-oxo-6-(3-piperazinium-4-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]butyric acid chloride 
• 1447331-52-3 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}propionic acid methyl ester 
• 1447331-70-5 3-{6-[3-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}butyric acid methyl ester 
• 179003-08-8 3-piperazine-4-yl-benzoic acid methyl ester 
• 261925-88-6 tert-butyl 4-(3-(hydroxymethyl)phenyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Th

Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive disease resulting from the deposition of toxic fibrils in tiss

ANTI-PAIN COMPOUND AND PREPARATION METHOD THEREFOR

Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.

ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF

The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region

Pyroglutamate-modified amyloid β peptides (pGlu-Aβ) are highly neurotoxic and promote the formation of amyloid plaques. The pGlu-Aβ peptides are generated by glutaminyl cyclase (QC), and recent clinical studies indicate that QC represents an alternative t

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

OXABOROLE ESTERS AND USES THEREOF

The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αiIbβ3

A series of novel RGD mimetics containing phthalimidine fragment was designed and synthesized. Their antiaggregative activity determined by Born's method was shown to be due to inhibition of fibrinogen binding to αIIbβ3. Molecular docking of RGD mimetics to αIIbβ3 receptor showed the key interactions in this complex, and also some correlations have been observed between values of biological activity and docking scores. The single crystal X-ray data were obtained for five mimetics.

Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture

The RNA replication machinery of HCV is a multi-subunit membrane-associated complex. NS5A has emerged as an active component of HCV replicase, possibly involved in regulation of viral replication and resistance to the antiviral effect of interferon. We report here substituted piperazinyl-N-(aryl)benzamides as potent inhibitors of HCV replication exerted via modulation of the dimerization of NS5A.

PYRROLIDINE DERIVATIVES AS ERK INHIBITORS

Disclosed are the ERK inhibitors of Formula (1.0): and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (1.0).